The New York Academy of Sciences
Understanding Environmental Disrupters in Lung Disease and Cancer
Posted March 19, 2020
Chronic inflammation can be caused by both intrinsic and extrinsic factors. In this eBriefing, experts examine the newest research on chronic inflammation and its role in lung disease and cancer, with emphasis on emerging therapeutic approaches that promote the resolution of inflammation.
In This Webinar, You’ll Learn:
- The intrinsic and extrinsic factors (including tobacco smoke) that drive chronic inflammation and can contribute to pro-tumorigenic environments.
- How pro-resolving pathways are compromised in cancer and chronic lung diseases such as COPD.
- How modulating resolution pathways could lead to the development of new therapies with high efficacy and fewer side effects.
Patricia Sime, MD
Virginia Commonwealth University
Patricia J. Sime received her MD training at the University of Edinburgh, Scotland, followed by training in the biology of scarring diseases at McMaster University, Canada. In 1999, she was recruited as faculty at the University of Rochester as a physician, educator and researcher. In 2019 she assumed the position as Chair of the Department of Internal Medicine at Virginia Commonwealth University. Dr. Sime leads a team of outstanding physicians and researchers focused on understanding the mechanisms and therapy of fibrotic lung diseases. She receives funding from the National Institutes of Health, the Department of Defense, Industry and Philanthropy.
Dipak Panigrahy, MD
Harvard Medical School
Dipak Panigrahy was accepted to medical school while still in high school at age 17, and graduated from the combined BA/MD program at Boston University Medical School. He trained with Roger Jenkins, who performed the 1st liver transplant in Boston. As a student and during his surgical training, Dr. Panigrahy worked closely with Judah Folkman, the father of angiogenesis, to develop mouse models for the study of tumor angiogenesis and angiogenesis-dependent regeneration. Dr. Panigrahy’s laboratory has published several studies in the emerging field of endogenous anti-inflammatory lipid autacoids such as resolvins and their role in inflammation resolution in cancer.